Chemical linkers in antibody-drug conjugates (ADCs) /
The covalent conjugation of potent cytotoxic agents to monoclonal antibodies, known as antibody-drug conjugates (ADCs) is a powerful approach in the field of targeted treatment of cancer. Clearly, both monoclonal antibody and cytotoxic payload are crucial elements in determining the clinical value o...
| Այլ հեղինակներ: | , |
|---|---|
| Ձևաչափ: | Licensed eBooks |
| Լեզու: | անգլերեն |
| Հրապարակվել է: |
Cambridge :
Royal Society of Chemistry,
[2022]
|
| Շարք: | ISSN.
|
| Առցանց հասանելիություն: | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=3123142 |
Բովանդակություն:
- Introduction to antibody-drug conjugates / John M. Lambert and F. L. van Delft
- Antibody conjugation technologies / G. T. Hermanson and F. L. van Delft
- Linker design and impact on ADC properties / M. Frigerio and N. Camper
- Non-cleavable linkers: permanently linked, for better or for worse / Julien Dugal-Tessier and Nareshkumar Jain
- Protease-sensitive linkers / S. Johannes, A. Sommer and H.-G. Lerchen
- Acid-labile linkers / E. A. Savoy, F. P. Olatunji, H. Yoon, N. Mesbahi, J. R. Knight and C. E. Berkman
- ADC linkers strategies for the release of alcohol-containing payloads / Jared T. Miller and L. Nathan Tumey
- Click-cleavable ADC linkers / R. Rossin and M. S. Robillard
- The use of uniform PEG compounds in the design of ADCs / M. W. Giese, R. H. Woodman, G. T. Hermanson and P. D. Davis
- Enhancing the polarity of the linker-drug in ADCs / Jorin Hoogenboom and Sander S. van Berkel
- Trastuzumab deruxtecan targeting HER2-expressing cancers with a Dxd-ADC system consisting of a novel protease-sensitive linker and DNA topoisomerase I inhibitor with a hydroxyl group / Takashi Nakada, Yuki Abe and Toshinori Agatsuma